AR078952A1 - Formulaciones de comprimidos revestidos - Google Patents

Formulaciones de comprimidos revestidos

Info

Publication number
AR078952A1
AR078952A1 ARP100104156A ARP100104156A AR078952A1 AR 078952 A1 AR078952 A1 AR 078952A1 AR P100104156 A ARP100104156 A AR P100104156A AR P100104156 A ARP100104156 A AR P100104156A AR 078952 A1 AR078952 A1 AR 078952A1
Authority
AR
Argentina
Prior art keywords
percent
weight
composition according
disintegrants
granulation
Prior art date
Application number
ARP100104156A
Other languages
English (en)
Inventor
Chimanlall Goolcharran
Mainuddin Mahmud
Muhammad Ashraf
Arwinder Singh Nagi
Krishnendu Ghosh
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078952(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AR078952A1 publication Critical patent/AR078952A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud proporciona formulaciones de comprimidos revestidos que comprenden maleato de neratinib, y procedimientos mejorados para fabricar dichos comprimidos revestidos. Reivindicacion 1: Una composicion farmacéuticamente aceptable caracterizada porque comprende: una granulacion que comprende los componentes intragranulares: (a) un 10-70 por ciento en peso de maleato de neratinib; (b) un 15-65 por ciento en peso de una o más cargas; (c) un 0-8 por ciento en peso de uno o más disgregantes: y (d) un 0,2-8 por ciento en peso de uno o más deslizantes; y (e) un 5-15 por ciento en peso de uno o más agentes modificadores de superficie, en la que la granulacion está combinada con componentes extragranulares, (f) un 1-25 por ciento en peso de una o más cargas; (g) un 0-8 por ciento en peso de uno o más disgregantes y (h) un 01-3 por ciento en peso de uno o más lubricantes. Reivindicacion 8: La composicion de acuerdo con la reivindicacion 4, caracterizada porque la cantidad de manitol y celulosa microcristalina, como componente intragranular, es de aproximadamente un 50 por ciento en peso. Reivindicacion 11: La composicion de acuerdo con la reivindicacion 4, caracterizada porque es en forma de una dosificacion oral de 40 mg, 80 mg o 240 mg. Reivindicacion 15: El procedimiento de acuerdo con la reivindicacion 13 o 14, caracterizado porque el agente modificador de superficie es povidona. Reivindicacion 16: Un procedimiento para tratar cáncer caracterizado porque comprende administrar una cantidad eficaz de una composicion de acuerdo con la reivindicacion 1.
ARP100104156A 2009-11-09 2010-11-09 Formulaciones de comprimidos revestidos AR078952A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25940309P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
AR078952A1 true AR078952A1 (es) 2011-12-14

Family

ID=43478191

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100104156A AR078952A1 (es) 2009-11-09 2010-11-09 Formulaciones de comprimidos revestidos
ARP180103329A AR114143A2 (es) 2009-11-09 2018-11-14 Formulaciones de comprimidos revestidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180103329A AR114143A2 (es) 2009-11-09 2018-11-14 Formulaciones de comprimidos revestidos

Country Status (21)

Country Link
US (2) US8518446B2 (es)
EP (3) EP4066821A1 (es)
JP (3) JP5835883B2 (es)
CN (2) CN103893140B (es)
AR (2) AR078952A1 (es)
AU (1) AU2010316683B2 (es)
CA (1) CA2780428C (es)
CY (1) CY1122330T1 (es)
DK (1) DK2498756T4 (es)
ES (1) ES2757882T5 (es)
FI (1) FI2498756T4 (es)
HR (1) HRP20192026T4 (es)
HU (1) HUE046606T2 (es)
LT (1) LT2498756T (es)
NZ (1) NZ599763A (es)
PL (1) PL2498756T5 (es)
PT (1) PT2498756T (es)
RS (1) RS59599B2 (es)
SI (1) SI2498756T2 (es)
TW (1) TWI466690B (es)
WO (1) WO2011055303A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN113975393A (zh) 2005-02-03 2022-01-28 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3443961B1 (en) 2008-06-17 2020-10-28 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
KR20140069340A (ko) 2008-08-04 2014-06-09 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
KR20160106211A (ko) 2009-04-06 2016-09-09 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
DK2498756T4 (da) * 2009-11-09 2023-03-20 Wyeth Llc Tabletformuleringer af neratinibmaleat
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20142454A1 (es) 2011-12-28 2015-02-07 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CA2903220C (en) 2013-03-15 2023-01-24 Qing Xu Aldehyde compounds and uses thereof for the modulation of hemoglobin
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9818967B2 (en) * 2013-06-28 2017-11-14 Universal Display Corporation Barrier covered microlens films
CN104337782A (zh) * 2013-08-02 2015-02-11 山东新时代药业有限公司 一种甲磺酸伊马替尼片剂
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015112850A2 (en) * 2014-01-23 2015-07-30 Wenle Xia Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
SG10201911668VA (en) 2014-02-07 2020-01-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10244991B2 (en) 2014-02-17 2019-04-02 Children's National Medical Center Method and system for providing recommendation for optimal execution of surgical procedures
ES2857523T3 (es) * 2014-07-25 2021-09-29 Novartis Ag Formulación en comprimido de 2-fluoro-N-metil-4-[7-(quinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
KR102305932B1 (ko) 2015-06-29 2021-09-28 플로로놀 인코퍼레이티드 갈조류의 고체 약제학적 조성물
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106831710A (zh) * 2015-12-07 2017-06-13 常州爱诺新睿医药技术有限公司 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN106913529B (zh) * 2015-12-24 2020-12-04 江苏恒瑞医药股份有限公司 一种来那替尼或其可药用盐药物组合物的制备方法
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
SG11201901873PA (en) * 2016-09-07 2019-03-28 Celgene Corp Tablet compositions
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018201131A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
WO2019080830A1 (zh) * 2017-10-24 2019-05-02 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物的药物组合物
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
US20220378788A1 (en) * 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
CA3181361A1 (en) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
AU2021291437B2 (en) * 2020-06-19 2024-07-04 Acerta Pharma B.V. Acalabrutinib maleate dosage forms
WO2023172958A1 (en) * 2022-03-08 2023-09-14 Onkosxcel Therapeutics, Llc Stable formulations of talabostat
WO2024187321A1 (zh) * 2023-03-10 2024-09-19 甫康（上海）健康科技有限责任公司 含有egfr抑制剂的药物组合物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7399865B2 (en) † 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
AR046544A1 (es) * 2003-10-15 2005-12-14 Wyeth Corp Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
AU2005295859A1 (en) * 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
ATE460937T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
EP2340837B1 (en) * 2005-11-11 2017-03-15 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
JP2007169273A (ja) * 2005-11-28 2007-07-05 Takeda Chem Ind Ltd 杵付着を改善した医薬製剤
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
AU2008206476A1 (en) * 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
TW200836774A (en) * 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
JP2009089982A (ja) * 2007-10-11 2009-04-30 Ohara Yakuhin Kogyo Kk 打錠用造粒物の造粒方法
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
MX2012000048A (es) * 2009-07-02 2012-01-27 Wyeth Llc Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos.
DK2498756T4 (da) * 2009-11-09 2023-03-20 Wyeth Llc Tabletformuleringer af neratinibmaleat

Also Published As

Publication number Publication date
PT2498756T (pt) 2019-11-26
ES2757882T3 (es) 2020-04-30
AU2010316683B2 (en) 2015-10-08
FI2498756T4 (fi) 2023-03-22
AR114143A2 (es) 2020-07-29
CN103893140A (zh) 2014-07-02
DK2498756T3 (da) 2019-11-25
NZ599763A (en) 2014-06-27
HRP20192026T4 (hr) 2023-03-31
CY1122330T1 (el) 2021-01-27
PL2498756T5 (pl) 2023-04-17
WO2011055303A1 (en) 2011-05-12
JP2015091882A (ja) 2015-05-14
SI2498756T2 (sl) 2023-04-28
CA2780428A1 (en) 2011-05-12
CN102724970A (zh) 2012-10-10
CN103893140B (zh) 2016-06-01
RS59599B1 (sr) 2020-01-31
SI2498756T1 (sl) 2020-01-31
DK2498756T4 (da) 2023-03-20
US20140004184A1 (en) 2014-01-02
LT2498756T (lt) 2019-12-10
EP2498756B1 (en) 2019-09-04
US8518446B2 (en) 2013-08-27
PL2498756T3 (pl) 2020-03-31
CN102724970B (zh) 2014-06-25
EP3566697B1 (en) 2024-09-11
EP4066821A1 (en) 2022-10-05
ES2757882T5 (es) 2023-05-10
JP5835883B2 (ja) 2015-12-24
EP3566697A1 (en) 2019-11-13
HRP20192026T1 (hr) 2020-02-07
RS59599B2 (sr) 2023-03-31
EP2498756B2 (en) 2023-02-15
TW201138774A (en) 2011-11-16
JP2017075192A (ja) 2017-04-20
JP2011098964A (ja) 2011-05-19
TWI466690B (zh) 2015-01-01
US8790708B2 (en) 2014-07-29
HUE046606T2 (hu) 2020-03-30
EP2498756A1 (en) 2012-09-19
AU2010316683A1 (en) 2012-05-24
CA2780428C (en) 2018-02-13
US20110111018A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
AR078952A1 (es) Formulaciones de comprimidos revestidos
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
BR112012023021A2 (pt) compostos de indazol e seus usos
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
PE20142440A1 (es) Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
MX2017010220A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
CR11724A (es) Agente para tratar enfermedades
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
AR077464A1 (es) Terapia de combinacion para el tratamiento de la diabetes
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
UA116334C2 (uk) Тверді форми дозування бендамустину
DOP2011000055A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
JP2013508289A5 (es)

Legal Events

Date Code Title Description
FC Refusal